CTRI/2016/09/007273已完成未知
A prospective, randomized, double blind, three-arm, parallel group, placebo controlled clinical Study to evaluate the Efficacy and Safety of Garlixir TM capsules (250 and 500 mg) in hyperlipidemia patients.
Biogen Extracts Pvt Ltd0 个研究点目标入组 78 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patient meeting the requirements of any one of the following parameters:-
- •.Total cholesterol (201-239 mg/dl),
- •.LDL-C (130-159 mg/dl),
- •.Triglycerides (161-230 mg/dl).
- •2.Patients willing to give a written informed consent along with audio video visual and willing to visit the site for a regular follow up.
- •3.Patients willing to abide by and comply with the study protocol requirements & restriction
- •BMI (body mass index) 19-30 kg/m2 (42-66 lb/m2)
- •4.Patient should be non-alcoholic.
- •5.Patients willing to abstain from usage of any NSAIDs during the study duration
- •6.Patients willing to abstain from heavy exercise (Jogging, Weight lifting etc.) during the study duration
排除标准
- •1.Patients with history or presence of
- •.Any clinically significant Respiratory system disorders
- •.Central nervous system disorders
- •.Reproductive system disorders
- •.Gastro intestinal disorders & having problems in swallowing or digesting.
- •.Diabetes (type I or II) or history of gestational diabetes
- •.Heart disease
- •.Active neoplasmâ??s
- •.Renal or liver disease
- •.Hyperthyroidism or Hypothyroidism
- •2.Patients who are pregnant, lactating or nursing.
- •3.Patients currently advised or are on lipid lowering medications (known to affect lipid metabolism, platelet function, or antioxidant status)
- •4.Patients currently advised or are on blood pressure medications.
- •5.Patient undergoing the following medications
- •.Protease inhibitors (e.g., indinavir, saquinavir), non-nucleoside reverse transcriptase inhibitors (NNRTIs such as nevirapine, efavirenz), isoniazid,
- •.Blood Thinners such as warfarin and heparin
- •.Anti-platelet drugs such as Aspirin & clopidogrel
- •.Calcium channel blockers including diltiazem
- •.Azole antifungals including ketoconazole, Fluconazole etc
- •.Medications with Garlic Supplements.
- •.Patients using oral contraceptives & Steroids.
- •.Patients smoking 20 or more cigarettes per day (Heavy smokers)
研究者
相似试验
已完成
3 期
Clinical trial on Mild and Moderate COVID-19CTRI/2021/12/038672Arna Immuno Ingredients Pvt Ltd AIP90
已完成
不适用
Compare the Efficacy and Safety of Mupirocin Cream USP, 2% in patients with Secondarily Infected Traumatic Skin LesionsCTRI/2020/08/027198Ms Cadila Healthcare Limited956
进行中(未招募)
1 期
Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosisendometriosis in reproductive-ageMedDRA version: 20.0 Level: PT Classification code 10014778 Term: Endometriosis System Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2018-002367-26-HUitaphar Laboratorios490
进行中(未招募)
1 期
Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosisendometriosis in reproductive-ageMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2018-002367-26-BGitaphar Laboratorios220
进行中(未招募)
1 期
Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosisEUCTR2018-002367-26-PLitaphar Laboratorios490
